Ensysce Biosciences, founded in La Jolla, United States, is a clinical-stage biotech company with a mission to develop safer prescription drugs that reduce abuse and prevent overdoses. The company focuses on creating innovative chemistry and transformative therapies, utilizing its proprietary TAAP™ platform to prevent drug abuse through methods such as snorting, extracting, injection, or chewing. Ensysce aims to address the prescription drug abuse epidemic by providing patients and prescribers with safer medication options.

Notable affiliated people include key scientists and executives with extensive experience in pharmaceutical development. Ensysce has received FDA “Fast Track” and “Breakthrough Therapy” designations, underscoring the potential impact of its technologies. The company's achievements in advancing safer drug formulations have positioned it as a significant player in combating prescription drug abuse, contributing to public health and safety.